|Mr. Matthew Pauls||Chairman & CEO||670.88k||N/A||1971|
|Mr. David L. Lowrance||CFO & Sec.||563.2k||N/A||1968|
|Dr. Badrul A. Chowdhury M.D., Ph.D.||Chief Medical Officer||766.49k||N/A||1959|
|Ms. Kate McCabe||Sr. VP of Legal Affairs||N/A||N/A||N/A|
|Ms. Anne Erickson||Sr. VP & Chief of Staff||N/A||N/A||N/A|
|Dr. Dhaval Desai M.D.||Head of Clinical Devel.||N/A||N/A||N/A|
|Brian Maurer||Head of Clinical Operations||N/A||N/A||N/A|
|Mr. Charles LaPree||Sr. VP of Global Regulatory Affairs & Quality Assurance||N/A||N/A||N/A|
|Dr. Peter Clarke Ph.D.||Exec. VP of Global Technical Operations||N/A||N/A||1960|
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Savara Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.